Featured Platforms

Custom Protein Generation

Mammalian- Derived Products

Microbial- Derived Products

Antibody Drug Conjugates

Bispecific Ab Platform

Technologies & Platforms

Article originally published in Bio Spectrum Asia September 2019  

Asia Building on Biologics Manufacturing

Featuring Chris Chen, Ph.D., CEO WuXi Biologics


After being a hub for generics drugs, Asia is now looking to capture the biologics market. The biologics manufacturing market size will grow by $ 36.58 billion during 2018-2022 and is expected to post a compound annual growth rate (CAGR) of more than nine per cent during the forecast period, according to a new report by Technavio. The market is driven by the growing awareness about their benefits in treating conditions that are hard to treat with conventional medicine. A key factor driving the growth of the market is the introduction of new biologic drugs for treating diseases. The demand for biologics for the more effective treatment of diseases is growing as synthetic drugs have several limitations. Therefore, the development of new biologics for the treatment of existing disorders and rare conditions is expected to fuel the growth of the biologics manufacturing industry. Asia has more than 300 biologics drugs under investigation.

Read the entire article HERE